{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:04:10Z","timestamp":1762866250749},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Bevacizumab, a recombinant humanized monoclonal antibody for vascular endothelial growth factor, has been widely used in various cancers offering substantial clinical benefit. It is reportedly associated with development of high-grade proteinuria and nephrotic syndrome with the histology of thrombotic microangiopathy, but there has been no report describing the development of immunoglobulin A nephropathy in bevacizumab-treated patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>A 68-year-old man with metastatic rectal cancer was treated with bevacizumab. He presented with hematuria and proteinuria 15 and 17\u00a0months, respectively, after bevacizumab initiation. Bevacizumab was stopped at 17\u00a0months. Renal biopsy at 19\u00a0months revealed immunoglobulin A nephropathy, with numerous paramesangial hemispherical deposits and thrombotic microangiopathy. Electron microscopy showed numerous paramesangial electron-dense deposits of various sizes, and subendothelial injuries. Proteinuria almost completely resolved 8\u00a0months after bevacizumab cessation, although hematuria persisted. Follow-up renal biopsy 11\u00a0months after bevacizumab cessation showed a marked decrease in mesangial immunoglobulin A deposits and paramesangial electron-dense deposits, which correlated with a gradual decrease in serum immunoglobulin A.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This is the first case report that confirmed histologically the development and resolution of immunoglobulin A nephropathy during and after bevacizumab therapy. This case shows that there may be other mechanisms of glomerular injury by bevacizumab besides glomerular endothelial injury leading to thrombotic microangiopathy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1756-0500-6-450","type":"journal-article","created":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T06:03:59Z","timestamp":1383977039000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature"],"prefix":"10.1186","volume":"6","author":[{"given":"Mayumi","family":"Yahata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izaya","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehisa","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Soma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,9]]},"reference":[{"key":"2472_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004, 25: 581-611. 10.1210\/er.2003-0027.","journal-title":"Endocr Rev"},{"key":"2472_CR2","volume-title":"Avastin\u00ae (Bevacizumab) Product Information","author":"Genentech, Inc.","year":"2009","unstructured":"Genentech, Inc.: Avastin\u00ae (Bevacizumab) Product Information. 2009, San Francisco, CA: Genentech, Inc."},{"key":"2472_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010, 21: 1381-1389. 10.1681\/ASN.2010020167.","journal-title":"J Am Soc Nephrol"},{"key":"2472_CR4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008, 358: 1129-1136. 10.1056\/NEJMoa0707330.","journal-title":"N Engl J Med"},{"key":"2472_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","volume":"8","author":"C Frangi\u00e9","year":"2007","unstructured":"Frangi\u00e9 C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D: Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007, 8: 177-178. 10.1016\/S1470-2045(07)70037-2.","journal-title":"Lancet Oncol"},{"key":"2472_CR6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2000","unstructured":"Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2000, 19: 843-850.","journal-title":"J Clin Oncol"},{"key":"2472_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007, 49: 186-193. 10.1053\/j.ajkd.2006.11.039.","journal-title":"Am J Kidney Dis"},{"key":"2472_CR8","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","volume":"65","author":"BF Schrijvers","year":"2004","unstructured":"Schrijvers BF, Flyvbjerg A, De Vriese AS: The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004, 65: 2003-2017. 10.1111\/j.1523-1755.2004.00621.x.","journal-title":"Kidney Int"},{"key":"2472_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ncpneph0476","volume":"3","author":"D Roncone","year":"2007","unstructured":"Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH: Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol. 2007, 3: 287-293. 10.1038\/ncpneph0476.","journal-title":"Nat Clin Pract Nephrol"},{"key":"2472_CR10","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, Devore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004, 22: 2184-2191. 10.1200\/JCO.2004.11.022.","journal-title":"J Clin Oncol"},{"key":"2472_CR11","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005, 23: 792-799. 10.1200\/JCO.2005.05.098.","journal-title":"J Clin Oncol"},{"key":"2472_CR12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ki.2008.256","volume":"74","author":"MB Stokes","year":"2008","unstructured":"Stokes MB, Erazo MC, D\u2019Agati VD: Glomerular disease related to anti-VEGF therapy. Kidney Int. 2008, 74: 1487-1491. 10.1038\/ki.2008.256.","journal-title":"Kidney Int"},{"key":"2472_CR13","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1053\/j.ajkd.2006.11.024","volume":"49","author":"BA George","year":"2007","unstructured":"George BA, Zhou XJ, Toto R: Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007, 49: E23-E29. 10.1053\/j.ajkd.2006.11.024.","journal-title":"Am J Kidney Dis"},{"key":"2472_CR14","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1345\/aph.1M670","volume":"44","author":"J Yeh","year":"2010","unstructured":"Yeh J, Frieze D, Martins R, Carr L: Clinical utility of bevacizumab for metastatic solid tumors. Ann Pharmacother. 2010, 44: 1010-1015. 10.1345\/aph.1M670.","journal-title":"Ann Pharmacother"},{"key":"2472_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/01913128809048473","volume":"12","author":"T Taguchi","year":"1988","unstructured":"Taguchi T, Von Bassewitz DB, Grundmann E, Takebayashi S: Ultrastructural changes of glomerular basement membrane in IgA nephritis: relationship to hematuria. Ultrastruct Pathol. 1988, 12: 17-26. 10.3109\/01913128809048473.","journal-title":"Ultrastruct Pathol"},{"key":"2472_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10157-009-0167-5","volume":"13","author":"IJ Jonkers","year":"2009","unstructured":"Jonkers IJ, van Buren M: Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin Exp Nephrol. 2009, 13: 397-401. 10.1007\/s10157-009-0167-5.","journal-title":"Clin Exp Nephrol"},{"key":"2472_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.5754\/hge08101","volume":"58","author":"B Melichar","year":"2011","unstructured":"Melichar B, Hyspler R, Kal\u00e1bov\u00e1 H, Dvor\u00e1k J, Tich\u00e1 A, Zad\u00e1k Z: Gastroduodenal, intestinal and colonic permeability during anticancer therapy. Hepatogastroenterology. 2011, 58: 1193-1199. 10.5754\/hge08101.","journal-title":"Hepatogastroenterology"},{"key":"2472_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-immunol-031210-101317","volume":"29","author":"A Cerutti","year":"2011","unstructured":"Cerutti A, Chen K, Chorny A: Immunoglobulin responses at the mucosal interface. Annu Rev Immunol. 2011, 29: 273-293. 10.1146\/annurev-immunol-031210-101317.","journal-title":"Annu Rev Immunol"},{"key":"2472_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semnephrol.2007.10.004","volume":"28","author":"S Pouria","year":"2008","unstructured":"Pouria S, Barratt J: Secondary IgA nephropathy. Semin Nephrol. 2008, 28: 27-37. 10.1016\/j.semnephrol.2007.10.004.","journal-title":"Semin Nephrol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-6-450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:09:06Z","timestamp":1630548546000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-6-450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2472"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-6-450","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,9]]},"assertion":[{"value":"30 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"450"}}